11β-Hydroxysteroid dehydrogenase type 1: Relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 14, Issue 10, 2012, Pages 869-881

  Pereira, C D ^a   Azevedo, I ^a   Monteiro, R ^a   Martins, M J ^a  

^a University of Porto   (Portugal)

Author keywords

11 hydroxysteroid dehydrogenase type 1; Dyslipidaemia; Glucose metabolism; Hypertension and insulin resistance; Metabolic syndrome; Nutritional and pharmacological modulation; Obesity; Type 2 diabetes mellitus

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 2' HYDROXYFLAVANONE; 3 HYDROXYFLAVONE; 6 HYDROXYFLAVONE; 7 HYDROXYFLAVONE; CAFFEINE; CARBOHYDRATE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CHRYSIN; CORTICOSTERONE; FLAVANONE; FLAVANONE DERIVATIVE; FLAVONE; FLAVONOID; GLUCOCORTICOID; GLUCOSE; GLYCYRRHETINIC ACID; GLYCYRRHETINIC ACID DERIVATIVE; HYDROCORTISONE; INCB 13739; INSULIN; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MK 0916; NATURAL PRODUCT; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PF 915275; POLYPHENOL DERIVATIVE; QUERCETIN; STREPTOZOCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADDISON DISEASE; ADIPOCYTE; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD SAMPLING; BODY COMPOSITION; BODY MASS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COFFEE; CORTICOSTERONE BLOOD LEVEL; CUSHING SYNDROME; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; EX VIVO STUDY; FOOD INTAKE; GENE EXPRESSION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL SUPPORT; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK FACTOR; RODENT; SCAVENGING SYSTEM; STREPTOZOCIN DIABETES; TRANSGENIC ANIMAL; TREATMENT RESPONSE;

EID: 84865975344     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01582.x     Document Type: Review

References (175)

1. Atanasov A, Odermatt A. Readjusting the glucocorticoid balance: an opportunity for modulators of 11beta-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets 2007; 7: 125-140.
2. Papadimitriou A, Priftis K. Regulation of the hypothalamic-pituitary-adrenal axis. Neuroimmunomodulation 2009; 16: 265-271.
3. Tomlinson J, Walker E, Bujalska I et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-866.
4. Gathercole L, Stewart P. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol 2010; 122: 21-27.
5. Seckl J, Walker B. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 2004; 15: 418-424.
6. Stewart P. Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome-11beta-hydroxysteroid dehydrogenase type 1. Clin Med 2005; 5: 142-146.
7. Pereira CD, Martins MJ, Azevedo I, Monteiro R. 11β-Hydroxysteroid dehydrogenase type 1 and the metabolic syndrome. In: Abduljabbar H ed. Steroids-Clinical Aspect. Rijeka, Croatia: InTech, 2011; 25-50.
8. Stewart P, Krozowski Z. 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm 1999; 57: 249-324.
9. Chapman K, Coutinho A, Gray M, Gilmour J, Savill J, Seckl J. Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response. Ann N Y Acad Sci 2006; 1088: 265-273.
10. Espindola-Antunes D, Kater C. Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity. Arq Bras Endocrinol Metabol 2007; 51: 1397-1403.
11. Anagnostis P, Athyros V, Tziomalos K, Karagiannis A, Mikhailidis D. The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis (clinical review). J Clin Endocrinol Metab 2009; 94: 2692-2701.
12. Bujalska I, Kumar S, Stewart P. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997; 349: 1210-1213.
13. Cooper M, Stewart P. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009; 94: 4645-4654.
14. Whorwood C, Donovan S, Wood P, Phillips D. Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endocrinol Metab 2001; 86: 2296-2308.
15. Walker B, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci 2006; 1083: 165-184.
16. Walker B, Connacher A, Lindsay R, Webb D, Edwards C. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995; 80: 3155-3159.
17. Jamieson P, Chapman K, Edwards C, Seckl J. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995; 136: 4754-4761.
18. Bujalska I, Walker E, Hewison M, Stewart P. A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002; 87: 1205-1210.
19. Bujalska I, Walker E, Tomlinson J, Hewison M, Stewart P. 11Beta-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res 2002; 28: 449-461.
20. Stewart P, Murry B, Mason J. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994; 79: 480-484.
21. Ozols J. Lumenal orientation and post-translational modifications of the liver microsomal 11 beta-hydroxysteroid dehydrogenase. J Biol Chem 1995; 270: 10360.
22. Draper N, Walker E, Bujalska I et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003; 34: 434-439.
23. Bujalska I, Draper N, Michailidou Z et al. Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1. J Mol Endocrinol 2005; 34: 675-684.
24. Atanasov A, Nashev L, Gelman L et al. Direct protein-protein interaction of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen. Biochim Biophys Acta 2008; 1783: 1536-1543.
25. Dzyakanchuk A, Balazs Z, Nashev L, Amrein K, Odermatt A. 11beta-Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high ratio of NADPH/NADP(+) and is stimulated by extracellular glucose. Mol Cell Endocrinol 2009; 301: 137-141.
26. Edwards C, Stewart P, Burt D et al. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986-989.
27. Rutters F, Nieuwenhuizen A, Lemmens S, Born J, Westerterp-Plantenga M. Hypothalamic-pituitary-adrenal (HPA) axis functioning in relation to body fat distribution. Clin Endocrinol (Oxf) 2010; 72: 738-743.
28. Reaven G. The metabolic syndrome: time to get off the merry-go-round? J Intern Med 2011; 269: 127-136.
29. Feldeisen S, Tucker K. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 2007; 32: 46-60.
30. Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
31. NCEP-ATPIII. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
32. Grundy S, Cleeman J, Daniels S et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
33. Alberti K, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
34. Johnson L, Weinstock R. The metabolic syndrome: concepts and controversy. Mayo Clin Proc 2006; 81: 1615-1620.
35. Alberti K, Eckel R, Grundy S et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
36. Baudrand R, Carvajal CA, Riquelme A et al. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients. Obes Surg 2010; 20: 77-83.
37. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion 2010; 83: 124-133.
38. Kim L, Nalls M, Eiriksdottir G et al. Associations of visceral and liver fat with the metabolic syndrome across the spectrum of obesity: the AGES-Reykjavik Study. Obesity (Silver Spring) 2011; 19: 1265-1271.
39. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 2011; 13: 692-702.
40. Phillips D, Barker D, Fall C et al. Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? J Clin Endocrinol Metab 1998; 83: 757-760.
41. Duclos M, Marquez Pereira P, Barat P, Gatta B, Roger P. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res 2005; 13: 1157-1166.
42. Misra M, Bredella M, Tsai P, Mendes N, Miller K, Klibanski A. Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls. Am J Physiol Endocrinol Metab 2008; 295: E385-E392.
43. Sen Y, Aygun D, Yilmaz E, Ayar A. Children and adolescents with obesity and the metabolic syndrome have high circulating cortisol levels. Neuro Endocrinol Lett 2008; 29: 141-145.
44. Weigensberg M, Toledo-Corral C, Goran M. Association between the metabolic syndrome and serum cortisol in overweight Latino youth. J Clin Endocrinol Metab 2008; 93: 1372-1378.
45. Walker B. Cortisol-cause and cure for metabolic syndrome? Diabet Med 2006; 23: 1281-1288.
46. Masuzaki H, Paterson J, Shinyama H et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-2170.
47. Wamil M, Seckl J. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007; 12: 504-520.
48. Masuzaki H, Yamamoto H, Kenyon C et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003; 112: 83-90.
49. van Raalte D, Ouwens D, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
50. London E, Castonguay T. Diet and the role of 11beta-hydroxysteroid dehydrogenase-1 on obesity. J Nutr Biochem 2009; 20: 485-493.
51. Morton N. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010; 316: 154-164.
52. Masuzaki H, Flier J. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)-a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 255-262.
53. Staab C, Maser E. 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J Steroid Biochem Mol Biol 2010; 119: 56-72.
54. Paterson J, Morton N, Fievet C et al. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 2004; 101: 7088-7093.
55. Morton N, Paterson J, Masuzaki H et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004; 53: 931-938.
56. Kotelevtsev Y, Holmes M, Burchell A et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997; 94: 14924-14929.
57. Morton N, Holmes M, Fievet C et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001; 276: 41293-41300.
58. Kershaw E, Morton N, Dhillon H, Ramage L, Seckl J, Flier J. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005; 54: 1023-1031.
59. Tomlinson J, Stewart P. Modulation of glucocorticoid action and the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 607-619.
60. Rask E, Olsson T, Soderberg S et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-1421.
61. Rask E, Walker B, Soderberg S et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 3330-3336.
62. Sandeep T, Andrew R, Homer N, Andrews R, Smith K, Walker B. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005; 54: 872-879.
63. Andrews R, Rooyackers O, Walker B. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 285-291.
64. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone → cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84: 1022-1027.
65. Valsamakis G, Anwar A, Tomlinson J et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 4755-4761.
66. Desbriere R, Vuaroqueaux V, Achard V et al. 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006; 14: 794-798.
67. Alberti L, Girola A, Gilardini L et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects. Int J Obes (Lond) 2007; 31: 1826-1831.
68. Simonyte K, Rask E, Naslund I et al. Obesity is accompanied by disturbances in peripheral glucocorticoid metabolism and changes in FA recycling. Obesity (Silver Spring) 2009; 17: 1982-1987.
69. Muñoz R, Carvajal C, Escalona A et al. 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg 2009; 19: 764-770.
70. Tomlinson J, Finney J, Gay C, Hughes B, Hughes S, Stewart P. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 2008; 57: 2652-2660.
71. Jang C, Obeyesekere V, Dilley R, Krozowski Z, Inder W, Alford F. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 3314-3320.
72. Stimson R, Andrew R, McAvoy N, Tripathi D, Hayes P, Walker B. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 2011; 60: 720-725.
73. Andrews R, Herlihy O, Livingstone D, Andrew R, Walker B. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 2002; 87: 5587-5593.
74. Simonyte K, Olsson T, Naslund I et al. Weight loss after gastric bypass surgery in women is followed by a metabolically favorable decrease in 11beta-hydroxysteroid dehydrogenase 1 expression in subcutaneous adipose tissue. J Clin Endocrinol Metab 2010; 95: 3527-3531.
75. Tomlinson J, Moore J, Clark P, Holder G, Shakespeare L, Stewart P. Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab 2004; 89: 2711-2716.
76. Karlsson C, Jernas M, Olsson B et al. Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis. Diabetes Res Clin Pract 2010; 88: 252-258.
77. Harvey AL. Natural products in drug discovery. Drug Discov Today 2008; 13: 894-901.
78. Quideau S, Deffieux D, Douat-Casassus C, Pouysegu L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew Chem Int Ed Engl 2011; 50: 586-621.
79. Xiao ZP, Peng ZY, Peng MJ, Yan WB, Ouyang YZ, Zhu HL. Flavonoids health benefits and their molecular mechanism. Mini Rev Med Chem 2011; 11: 169-177.
80. Torres-Piedra M, Ortiz-Andrade R, Villalobos-Molina R et al. A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11beta-hydroxysteroid dehydrogenase type 1 inhibition. Eur J Med Chem 2010; 45: 2606-2612.
81. Schweizer RA, Atanasov AG, Frey BM, Odermatt A. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol 2003; 212: 41-49.
82. Ferruzzi MG. The influence of beverage composition on delivery of phenolic compounds from coffee and tea. Physiol Behav 2010; 100: 33-41.
83. Rustenbeck I. Unconventional antidiabetic agents. Med Monatsschr Pharm 2007; 30: 131-137.
84. van Dam RM. Coffee and type 2 diabetes: from beans to beta-cells. Nutr Metab Cardiovasc Dis 2006; 16: 69-77.
85. van Dam RM, Feskens EJ. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2002; 360: 1477-1478.
86. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 2005; 294: 97-104.
87. Atanasov A, Dzyakanchuk A, Schweizer R, Nashev L, Maurer E, Odermatt A. Coffee inhibits the reactivation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: a glucocorticoid connection in the anti-diabetic action of coffee? FEBS Lett 2006; 580: 4081-4085.
88. Li RS, Nakagawa Y, Nakanishi T, Fujisawa Y, Ohzeki T. Different responsiveness in body weight and hepatic 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 mrna to 11beta-HSD inhibition by glycyrrhetinic acid treatment in obese and lean zucker rats. Metabolism 2004; 53: 600-606.
89. Classen-Houben D, Schuster D, Da Cunha T et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid. J Steroid Biochem Mol Biol 2009; 113: 248-252.
90. Su X, Vicker N, Lawrence H et al. Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives. J Steroid Biochem Mol Biol 2007; 104: 312-320.
91. Su X, Lawrence H, Ganeshapillai D et al. Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases. Bioorg Med Chem 2004; 12: 4439-4457.
92. Vicker N, Su X, Lawrence H et al. A novel 18 beta-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11 beta-hydroxysteroid dehydrogenase 2. Bioorg Med Chem Lett 2004; 14: 3263-3267.
93. Drake A, Livingstone D, Andrew R, Seckl J, Morton N, Walker B. Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats. Endocrinology 2005; 146: 913-919.
94. Morton N, Ramage L, Seckl J. Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 2004; 145: 2707-2712.
95. Black BL, Croom J, Eisen EJ, Petro AE, Edwards CL, Surwit RS. Differential effects of fat and sucrose on body composition in A/J and C57BL/6 mice. Metabolism 1998; 47: 1354-1359.
96. Surwit RS, Wang S, Petro AE et al. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Proc Natl Acad Sci U S A 1998; 95: 4061-4065.
97. Vara Prasad S, Jeya Kumar S, Kumar P, Qadri S, Vajreswari A. Dietary fatty acid composition alters 11beta-hydroxysteroid dehydrogenase type 1 gene expression in rat retroperitoneal white adipose tissue. Lipids Health Dis 2010; 9: 111.
98. London E, Castonguay TW. High fructose diets increase 11beta-hydroxysteroid dehydrogenase type 1 in liver and visceral adipose in rats within 24-h exposure. Obesity (Silver Spring) 2011; 19: 925-932.
99. London E, Lala G, Berger R et al. Sucrose access differentially modifies 11beta-hydroxysteroid dehydrogenase-1 and hexose-6-phosphate dehydrogenase message in liver and adipose tissue in rats. J Nutr 2007; 137: 2616-2621.
100. Ouyang X, Cirillo P, Sautin Y et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008; 48: 993-999.
101. Stanhope KL, Schwarz JM, Keim NL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322-1334.
102. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010; 90: 23-46.
103. Tappy L, Le KA, Tran C, Paquot N. Fructose and metabolic diseases: new findings, new questions. Nutrition 2010; 26: 1044-1049.
104. Cho GJ, Park HT, Shin JH et al. Calcium intake is inversely associated with metabolic syndrome in postmenopausal women: Korea National Health and Nutrition Survey, 2001 and 2005. Menopause 2009; 16: 992-997.
105. Van Leer EM, Seidell JC, Kromhout D. Dietary calcium, potassium, magnesium and blood pressure in the Netherlands. Int J Epidemiol 1995; 24: 1117-1123.
106. Yokota K, Kato M, Lister F et al. Clinical efficacy of magnesium supplementation in patients with type 2 diabetes. J Am Coll Nutr 2004; 23: 506S-509S.
107. Takaya J, Iharada A, Okihana H, Kaneko K. Upregulation of hepatic 11beta-hydroxysteroid dehydrogenase-1 expression in calcium-deficient rats. Ann Nutr Metab 2011; 59: 73-78.
108. Takaya J, Kaneko K. Small for gestational age and magnesium in cord blood platelets: intrauterine magnesium deficiency may induce metabolic syndrome in later life. J Pregnancy 2011; 2011: 270474.
109. Takaya J, Iharada A, Okihana H, Kaneko K. Magnesium deficiency in pregnant rats alters methylation of specific cytosines in the hepatic hydroxysteroid dehydrogenase-2 promoter of the offspring. Epigenetics 2011; 6: 573-578.
110. Cho Y, Kim C, Cheon H. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors. Anal Biochem 2009; 392: 110-116.
111. Webster SP, Binnie M, McConnell KM et al. Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1, 5-substituted 1H-tetrazoles. Bioorg Med Chem Lett 2010; 20: 3265-3271.
112. Coppola G, Kukkola P, Stanton J et al. Perhydroquinolylbenzamides as novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2005; 48: 6696-6712.
113. Yuan C, St Jean DJ Jr, Liu Q et al. The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 2007; 17: 6056-6061.
114. Hult M, Shafqat N, Elleby B et al. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol Cell Endocrinol 2006; 248: 26-33.
115. Julian L, Wang Z, Bostick T et al. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. J Med Chem 2008; 51: 3953-3960.
116. Siu M, Johnson TO, Wang Y et al. N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: discovery of PF-915275. Bioorg Med Chem Lett 2009; 19: 3493-3497.
117. Tu H, Powers JP, Liu J et al. Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem 2008; 16: 8922-8931.
118. Bujalska I, Gathercole L, Tomlinson J et al. A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol 2008; 197: 297-307.
119. Courtney R, Stewart P, Toh M, Ndongo M, Calle R, Hirshberg B. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J Clin Endocrinol Metab 2008; 93: 550-556.
120. Bhat B, Hosea N, Fanjul A et al. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther 2008; 324: 299-305.
121. Feig P, Shah S, Hermanowski-Vosatka A et al. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011; 13: 498-504.
122. Rosenstock J, Banarer S, Fonseca V et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010; 33: 1516-1522.
123. Morgan S, Sherlock M, Gathercole L et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009; 58: 2506-2515.
124. Barf T, Vallgarda J, Emond R et al. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002; 45: 3813-3815.
125. Wang SJ, Birtles S, de Schoolmeester J et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia 2006; 49: 1333-1337.
126. Liu J, Wang L, Zhang A et al. Adipose tissue-targeted 11beta-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity. Endocr J 2011; 58: 199-209.
127. Alberts P, Nilsson C, Selen G et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003; 144: 4755-4762.
128. Alberts P, Engblom L, Edling N et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002; 45: 1528-1532.
129. Johansson L, Fotsch C, Bartberger M et al. 2-amino-1, 3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice. J Med Chem 2008; 51: 2933-2943.
130. Hermanowski-Vosatka A, Balkovec J, Cheng K et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202: 517-527.
131. Park J, Rhee S, Kang N et al. Anti-diabetic and anti-adipogenic effects of a novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1, 1-dioxo-2H-1, 2-benzothiazine-2-yl-1-phenylethanone (KR-66344). Biochem Pharmacol 2011; 81: 1028-1035.
132. Ye YL, Zhou Z, Zou HJ et al. Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem 2009; 17: 5722-5732.
133. Berthiaume M, Laplante M, Festuccia W et al. 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab 2007; 293: E1045-E1052.
134. Berthiaume M, Laplante M, Festuccia W et al. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2007; 148: 2391-2397.
135. Zhang X, Zhou Z, Yang H et al. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice. Bioorg Med Chem Lett 2009; 19: 4455-4458.
136. Wan ZK, Chenail E, Xiang J et al. Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. J Med Chem 2009; 52: 5449-5461.
137. Véniant MM, Hale C, Hungate RW et al. Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S, 2S, 4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5 H)-one (AMG 221). J Med Chem 2010; 53: 4481-4487.
138. Sundbom M, Kaiser C, Bjorkstrand E et al. Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol 2008; 8: 3.
139. Lloyd D, Helmering J, Cordover D et al. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab 2009; 11: 688-699.
140. Hale C, Veniant M, Wang Z et al. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor. Chem Biol Drug Des 2008; 71: 36-44.
141. Stewart P, Tomlinson J. Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both? Diabetes 2009; 58: 14-15.
142. Hughes K, Webster S, Walker B. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 2008; 17: 481-496.
143. Ge R, Huang Y, Liang G, Li X. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr Med Chem 2010; 17: 412-422.
144. Morgan S, Tomlinson J. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010; 19: 1067-1076.
145. Tiwari A. INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes. IDrugs 2010; 13: 266-275.
146. Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem 2008; 8: 702-710.
147. Hollis G, Huber R. 11beta-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 1-6.
148. Shah S, Hermanowski-Vosatka A, Gibson K et al. Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertens 2011; 5: 166-176.
149. Shah U, Boyle C, Chackalamannil S et al. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett 2010; 20: 1551-1554.
150. Wan ZK, Chenail E, Li HQ et al. Synthesis of potent and orally efficacious 11beta-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016. J Org Chem 2011; 76: 7048-7055.
151. Wang H, Robl JA, Hamann LG et al. Generation of 3, 8-substituted 1, 2, 4-triazolopyridines as potent inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1). Bioorg Med Chem Lett 2011; 21: 4146-4149.
152. Sano S, Nakagawa Y, Yamaguchi R et al. Carbenoxolone alters the morphology of adipose tissues and downregulates genes involved in adipogenesis, glucose transport and lipid metabolism in high-fat diet-fed mice. Horm Metab Res 2012; 44: 15-20.
153. Livingstone D, Walker B. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 2003; 305: 167-172.
154. Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity. Biol Chem 2008; 389: 441-445.
155. Monder C, Stewart P, Lakshmi V, Valentino R, Burt D, Edwards C. Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 1989; 125: 1046-1053.
156. Tomlinson J, Sherlock M, Hughes B et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 2007; 92: 857-864.
157. Feng Y, Huang S, Dou W et al. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Br J Pharmacol 2010; 161: 113-126.
158. Chalbot S, Morfin R. Dehydroepiandrosterone metabolites and their interactions in humans. Drug Metabol Drug Interact 2006; 22: 1-23.
159. Latif SA, Pardo H, Hardy M, Morris D. Endogenous selective inhibitors of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin. Mol Cell Endocrinol 2005; 243: 43-50.
160. Maeda Y, Naganuma S, Niina I et al. Effects of bile acids on rat hepatic microsomal type I 11beta-hydroxysteroid dehydrogenase. Steroids 2010; 75: 164-168.
161. Diederich S, Grossmann C, Hanke B et al. In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I. Eur J Endocrinol 2000; 142: 200-207.
162. Morris D, Souness G, Latif S, Hardy M, Brem A. Effect of chenodeoxycholic acid on 11beta-hydroxysteroid dehydrogenase in various target tissues. Metabolism 2004; 53: 811-816.
163. Odermatt A, Nashev L. The glucocorticoid-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: physiological and toxicological considerations. J Steroid Biochem Mol Biol 2010; 119: 1-13.
164. Blum A, Loerz C, Martin HJ, Staab-Weijnitz CA, Maser E. Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11beta-hydroxysteroid dehydrogenase type 1 inhibitor. J Steroid Biochem Mol Biol 2012; 128: 51-55.
165. Tagawa N, Minamitani E, Yamaguchi Y, Kobayashi Y. Alternative mechanism for anti-obesity effect of dehydroepiandrosterone: possible contribution of 11beta-hydroxysteroid dehydrogenase type 1 inhibition in rodent adipose tissue. Steroids 2011; 76: 1546-1553.
166. Jellinck P, Monder C, McEwen B, Sakai R. Differential inhibition of 11 beta-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues. J Steroid Biochem Mol Biol 1993; 46: 209-213.
167. Abdallah B, Beck-Nielsen H, Gaster M. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest 2005; 35: 627-634.
168. Balázs Z, Nashev L, Chandsawangbhuwana C, Baker M, Odermatt A. Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11beta-hydroxysteroid dehydrogenase 1. Mol Cell Endocrinol 2009; 301: 117-122.
169. Wamil M, Andrew R, Chapman K, Street J, Morton N, Seckl J. 7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type. Endocrinology 2008; 149: 5909-5918.
170. Diederich S, Quinkler M, Mai K et al. In vivo activity of 11beta-hydroxysteroid dehydrogenase type 1 in man: effects of prednisolone and chenodesoxycholic acid. Horm Metab Res 2011; 43: 66-71.
171. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2: 821-824.
172. Stewart PM, Wallace AM, Atherden SM, Shearing CH, Edwards CR. Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Sci (Lond) 1990; 78: 49-54.
173. Ferrari P. The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 2010; 1802: 1178-1187.
174. Palermo M, Quinkler M, Stewart P. Apparent mineralocorticoid excess syndrome: an overview. Arq Bras Endocrinol Metabol 2004; 48: 687-696.
175. Funder J, Pearce P, Smith R, Smith A. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-585.